Trade with Eva: Analytics in action >>

Thursday, August 1, 2019

-=Acorda Therapeutics (ACOR) reported earnings on Thur 1 Aug 2019 (a/h)

Acorda Therapeutics (ACOR) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to earnings of $1.40 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 48.11%. A quarter ago, it was expected that this drugmaker would post a loss of $0.97 per share when it actually produced a loss of $0.56, delivering a surprise of 42.27%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Acorda, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $50.05 million for the quarter ended June 2019, surpassing the Zacks Consensus Estimate by 91.32%. This compares to year-ago revenues of $153.30 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Acorda shares have lost about 55.5% since the beginning of the year versus the S&P 500's gain of 18.9%.

No comments:

Post a Comment